HemaFlo Therapeutic’s Technology
Drag-reducing polymers suppress flow disturbances, flatten the flow velocity profile, and increase the wall shear force in blood vessels as shown in this schematic (click image on right).
As a result of these drag-reducing polymer properties:
- Flow rate is increased (2X or more) at a constant blood pressure
- Arteries dilate
- Oxygen exchange improves
Resulting in a huge increase in tissue perfusion and oxygenation.
These effects are illustrated in a study by Marina Kameneva et al1 where they induced a severe hemorrhagic shock in rats and then resuscitated them with standard Plasmalyte/dextran solution (control) or with the same fluid containing a drag-reducing polymer extracted from aloe vera, a synthetic drag-reducing polymer PEG-3500, and PEG-200 which is too short to have DRP properties. 80% or more of the control or PEG-200 treated animals died while none of the DRP treated animals died. Surprisingly, after the two hour experiment (END) the animals that received DRP had higher tissue perfusion (TP) values than before the hemorrhage treatment (BASE) at lower mean arterial pressure (MAP)!
HemaFlo is developing a DRP product, HFT-012, for the treatment of acute kidney injury. Contact HemaFlo for assistance in developing DRP products for other medical indications.
1. Kemeneva, et al, Biorheology 41:53-64, 2004.